
    
      This multicenter, double-blind, placebo-controlled, randomized (1:1) discontinuation study is
      a 4-part study designed to evaluate the efficacy and safety of multiple dose administration
      of amifampridine phosphate in patients with LEMS. Data from parts 2 and 3 (the double-blind
      parts of the study) are presented in this record.
    
  